- About Us
- Dermarite Academy
- News & Insights
- Contact Us
North Bergen, New Jersey – June 2017 – DermaRite Industries, LLC (“DermaRite”) announced it has named Barbara J. Osborne as Chief Commercial Officer of the company. In her role, Ms. Osborne will be responsible for driving the company’s sales and commercialization efforts.
Ms. Osborne is an experienced healthcare industry executive. Most recently, she served as the U.S. Division President and CEO of LEO Pharma. Previously, Ms. Osborne served as the President of Mölnlycke Health Care’s U.S. Wound Care business.
Ms. Osborne has a broad background encompassing sales, marketing, finance, accounting, business development and R&D. During her tenure in the healthcare industry, she also held senior leadership positions at C.R. Bard, Microtek Medical, and Covidien.
“Ms. Osborne is joining the company at a key stage in our development,” says Naftali Minzer, Chief Executive Officer of DermaRite. “Her extensive experience in the wound care industry and her proven success leading and growing similar size organizations will be a strong addition to our business as we position the company for future growth.”
“I am honored to be joining DermaRite, and I am looking forward to building on the company’s strong foundation,” commented Ms. Osborne. “It is an exciting time to impact the next growth phase of the company.”
Ms. Osborne holds a Master of Science in Accounting from New York University’s Stern School of Business and received her undergraduate degree from Colgate University.
About DermaRite Industries:
DermaRite Industries has been providing high-quality, clinically effective and cost-effective skin and wound care products to nursing homes, home health agencies, hospice and wound clinics for over 20 years. Based in North Bergen, New Jersey, the company’s Healing In D.E.P.T.H. program provides caregivers with the tools and services needed to assure optimal care.
For more information about DermaRite, visit Dermarite.com.
Please direct all inquiries to Yalitza Hernandez, email@example.com, 973-569-9000 x113.
An independent taste test conducted on November 8, 2016 revealed that over 70% of participants preferred the taste of ProHeal™ Liquid Protein when compared to the leading brand.
The blind taste test comparison occurred on 11/8/16 in a dining room of a post-acute care setting using a sample of convenience that included 20 residents and 5 staff members. The residents were from assisted living, long-term care and rehabilitation. All participants were informed of the taste trial for the 2 cherry flavored products (ProHeal™ and ProStat SF®). No food allergies were reported. The facility’s staff conducted the trial and no manufacturer representative was present during the taste test. The samples were unlabeled and the identities of the products were known only to the testers. The subjects reported their preference based on taste after sampling both products.
Staff reported preference (n=5): Prostat=1 (20%); ProHeal=4 (80%).
Residents reported preference (n=20): Prostat=5 (25%); ProHeal=14 (70%); no preference=1 (5%). Statistical analysis using one sample t-test between the percents shows a statistically significant (p=.031) difference in test preference in favor of ProHeal.
Cumulative staff & residents (n=25): Prostat=6 (24%); ProHeal=18 (72%); no preference=1 (4%). Statistical analysis using one sample t-test between the percents shows a statistically significant (p=.010) difference in test preference in favor of ProHeal.
This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.